Nuvation Bio NUVB Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five?
- Nuvation Bio (NUVB) reported debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five of $142.37M in Q4 2025.
- How has Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five changed year-over-year?
- Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five increased by 71.7% year-over-year, from $82.94M to $142.37M.
- What is the long-term trend for Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five?
- Over 4 years (2021 to 2025), Nuvation Bio's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five has grown at a -15.6% compound annual growth rate (CAGR), from $280.35M to $142.37M.